

Konrad Stawiski

Radiation oncologist and clinical-translational researcher

Board-certified radiation oncologist and clinical-translational researcher focused on GU/GI radiotherapy, bladder/prostate/rectal cancer care, radiomics, omics biomarkers, radiation-toxicity modeling, and practical medical AI.

Contact and profiles: konrad@konsta.com.pl; [Harvard Catalyst](#); [ORCID](#); [PubMed](#); [OpenAlex](#); [Google Scholar](#); [GitHub](#).

Current roles and focus

- **Visiting Assistant Professor of Radiation Oncology**, Dana-Farber Cancer Institute, Boston, MA, USA.
- **Assistant Professor**, Department of Biostatistics and Translational Medicine, Medical University of Lodz; supervisor of the Artificial Intelligence in Oncology Students' Scientific Group.
- **Radiation Oncologist and Deputy Head of Department of Brachytherapy and General Oncology**, Copernicus Memorial Hospital in Lodz; deputy clinical lead for a 34-bed ward.
- Clinical scope: broad radiotherapy practice with special focus on genitourinary and gastrointestinal cancers, including prostate, bladder, and rectal cancer; SBRT/SRS, brachytherapy, radiochemotherapy, and radioimmunotherapy.

Summary

Konrad Stawiski combines clinical GU/GI radiation oncology with translational oncology, radiomics, omics biomarkers, radiation-toxicity modeling, and practical medical AI.

The curated Google Scholar publication list contains 93 records; the profile reports an h-index of 19 and 1,095 citations. He is Partner PI and Polish group lead in the ERA PerMed miRPOC consortium, PI of the NCN PRELUDIUM and Radonek-AI projects, and co-inventor on circulating microRNA patent families for pancreatic and ovarian cancer.

His clinical and translational portfolio includes phase I/II-III oncology trial work, open research software, selected digital-health tools, editorial service as an Editorial Board Member of BMC Cancer, and membership in the ESTRO AI in RT Focus Group.

International collaboration

OpenAlex currently identifies publication coauthors affiliated with 16 countries outside Poland. Most frequently represented: United States (44), United Kingdom (7), Greece (5), Hungary (5).

Publication collaboration footprint

Coauthor-affiliation countries recorded for OpenAlex works



Poland is outlined as the home base. Source: OpenAlex; each work is counted once per country.

Selected publications and contributions

- **First author / GU translational oncology:** Stawiski K, Perera-Bel J, Rodriguez-Vida A, Juanpere N, Lee J, Michaud DE, Guerriero JL, Mouw KW, Bamias A, Carvalho FLF, Bellmunt J. **Tumor B-cell infiltration in platinum-treated advanced muscle-invasive urothelial carcinoma.** *Molecular Oncology*. 2026 Jun 1. doi: [10.1002/1878-0261.70276](https://doi.org/10.1002/1878-0261.70276).
- **Bladder cancer / DFCI-Broad collaboration:** Zhou Y, Borcsok J, Adib E, Kamran SC, Neil AJ, Stawiski K, et al. **ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer.** *Science Advances*. 2023;9:eadg2263. doi: [10.1126/sciadv.adg2263](https://doi.org/10.1126/sciadv.adg2263).

- **Clinical AI / urologic oncology:** Jobczyk M, Stawiski K, Kaszkowiak M, Rajwa P, Rozanski W, Soria F, et al. **Deep learning-based recalibration of the CUETO and EORTC prediction tools for recurrence and progression of non-muscle-invasive bladder cancer.** *European Urology Oncology*. 2022;5:109-112.
- **Research software / omics modeling:** Stawiski K, Kaszkowiak M, Mikulski D, Hogendorf P, Durczynski A, et al. **OmicSelector: automatic feature selection and deep learning modeling for omic experiments.** *bioRxiv*. 2022. doi: [10.1101/2022.06.01.494299](https://doi.org/10.1101/2022.06.01.494299).
- **miRNA biomarker validation:** Stawiski K, Fortner RT, Pestarino L, Umu SU, Kaaks R, Rounge TB, et al. **Validation of miRNA signatures for ovarian cancer earlier detection in the pre-diagnosis setting using machine learning approaches.** *Frontiers in Oncology*. 2024;14:1389066.
- **Radiation toxicity / dose-volume analytics:** Nowicka Z, Kuna K, Laszczych M, Lazar-Poniatowska M, Sobocki BK, Stawiski K, et al. **Dose-volume metric-based prediction of radiotherapy-induced lymphocyte loss.** *Physics and Imaging in Radiation Oncology*. 2024;30:100593.

Grants, awards, patents

- ERA PerMed miRPOC, Joint Transnational Call 2022: total consortium budget approximately EUR 1,000,000; **Partner PI / Polish group lead** at Medical University of Lodz.
- Prof. Franciszek Walczak NAWA Programme Scholarship, 2025: one of 31 awardees; six-month Dana-Farber / Harvard Medical School fellowship on bladder-preserving treatment.
- **PI-led projects:** NCN PRELUDIUM, 2019-2022, deep neural networks for miRNA profiles in pancreatic cancer; Radonek-AI, 2023-2024, virtual oncology patient assistant (PLN 70,000).
- Patent families: circulating microRNA signatures for pancreatic cancer and ovarian cancer.

Clinical trials and research software

- Selected commercial clinical trials as subinvestigator / site clinical team: TALAPRO-2 (mCRPC), KEYNOTE-867 (locally advanced NSCLC chemoradiotherapy + pembrolizumab), KEYNOTE-689 (head-and-neck cancer), CALLA (cervical cancer chemoradiotherapy + durvalumab), NC-6004-009 (advanced solid tumors).
- **Radiotherapy data tools:** RTpipeline for DICOM RT, dose-volume, radiomics, and machine-learning workflows; rect-ril for severe radiation-induced lymphopenia prediction in rectal cancer (Zenodo DOI [10.5281/zenodo.19595346](https://doi.org/10.5281/zenodo.19595346)).
- **Omics and variant-analysis software:** Somatic Likelihood Tiering for tumor-only WES variant triage; OmicSelector / OmicApp for feature selection and deep-learning modeling.
- **Notatnik Medyczny:** selected digital-health project for structured clinical documentation workflows; public ADK hackathon prototype at github.com/kstawiski/notatnik-adk-slice-public.